About BenchSci
BenchSci operates in the biotechnology sector, specializing in preclinical research and development. The company uses artificial intelligence and machine learning to create a detailed map of disease biology, which helps scientists understand existing research and improve their R&D efficiency. Its main product, ASCEND, is a platform that extracts evidence from various data sources to assist scientists in hypothesis generation and risk identification. BenchSci aims to enhance research capabilities and reduce risks in preclinical studies.
Toronto, CanadaHeadquarters
2015Year Founded
$156.6MTotal Funding
SERIES_DCompany Stage
AI & Machine Learning, BiotechnologyIndustries
201-500Employees
Benefits
Remote-first culture
Equity options
15 days vacation + additional day every year
Unlimited flex time
Comprehensive health & dental benefits
Psychotherapist services
Annual Learning & Development budget
Home office set-up budget
Wellness, lifestyle & productivity spending account
Risks
17% workforce reduction may impact morale and innovation at BenchSci.
Heavy reliance on external funding poses financial risks if future rounds falter.
Rapid team expansion could lead to integration challenges and inefficiencies.
Differentiation
BenchSci's ASCEND platform uses AI to map disease biology for drug discovery.
ASCEND helps scientists identify risks and generate hypotheses in preclinical R&D.
BenchSci's AI Reagent Selector improves reagent selection efficiency in drug development.
Upsides
$95M Series D funding boosts BenchSci's AI platform development and market reach.
Generative AI integration enhances ASCEND's predictive capabilities for hypothesis generation.
Recognition as a Best Workplace for Inclusion attracts top talent and fosters innovation.
Funding
Total raised$156.59 M
Latest valuation$475.00 M
StageSERIES_D
SERIES D
4/30/2023$70
$475.00 MSERIES C
12/31/2021$46
$315.00 MSERIES B
1/31/2021$10
$50.00 MSERIES A
5/31/2019$5
$25.50 MGRANT
12/31/2014N/A